bpc 157 tb500 wolverine stack BPC-157 + TB-500 5/5mg 10/10mg | Tissue Repair Research Combination BPC-157 and TB-500: The Wolverine

In two Phase 2 clinical trials covering stasis and pressure ulcers, TB4 accelerated complete wound closure by almost a month in patients who achieved full healing representing one of the most substantial healing acceleration outcomes observed for a peptide compound in a controlled clinical investigation

Even if clinical trials suggest tolerability, the real-world risk profile changes when: the source and purity of the peptide are uncertain, its used in different routes than studied, its used in stacked protocols with other drugs, its used in populations the trials didnt represent

Throughout the 4-year transition period, from CY 2010 to CY 2013, we gradually incorporated the AMA PPIS data into the PFS rates, replacing the previous data sources

K.MurselovicT.RadonicJ.DuzelV.et al (2016)